Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC

Purpose: The study investigated the impact of TP53 mutations on the clinical efficacy of first-generation EGFR-tyrosine kinase inhibitors (TKIs) in Chinese patients with advanced or recurrent non-small-cell lung cancer (NSCLC). Patients and methods: Tissues from 163 NSCLC patients at the Affiliated...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Manag Res
Main Authors: Hou, Helei, Qin, Kang, Liang, Yu, Zhang, Chuantao, Liu, Dong, Jiang, Haiping, Liu, Kewei, Zhu, Jingjuan, Lv, Hongying, Li, Tianjun, Zhang, Xiaochun
Format: Artigo
Language:Inglês
Published: Dove 2019
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594053/
https://ncbi.nlm.nih.gov/pubmed/31417310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S201513
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items